


 Cite this: *RSC Adv.*, 2024, 14, 37227

# Design and synthesis of a novel curcumin–combretastatin A4 molecular skeleton: two pharmacophores†

 Pravinkamaraj Ponraj and Saravanakumar Rajendran \*

The logical design and synthesis of a novel compound combretastatin A-4-integrated curcumin is presented. Claisen condensation of phenylacetone with ethyl acetates formed 1,5-diphenylpentane-2,4-dione. Condensation of the dione with benzaldehyde *via* a modified Pabon procedure formed combretastatin A-4-integrated curcumin. The single-crystal X-ray structure of one of the CA-4 integrated CURs was established as a representative example. Curcumin (CUR) and combretastatin A-4 (CA-4) are well-known bioactive natural products; however, their poor pharmacokinetic profiles and *cis*–*trans* isomerization under *in vivo* conditions, respectively, have limited their biological applications. Herein, coupling of an aryl group at the olefinic C2 and/or C6 position of CUR integrates a CA-4-like structure with *cis*-configuration locked to CUR. At the same time, aryl coupling created steric hindrance around the olefinic bond and could resist the reductive metabolism of CUR and contribute to a better pharmacokinetic profile. Remarkably, this modification did not disturb the functional groups in both the natural products (CUR and CA-4), which is promising for their therapeutic effects. Thus, the synthesized CA-4-integrated CUR molecular architecture offers a new molecular skeleton to be explored for bio-application.

 Received 13th September 2024  
 Accepted 4th November 2024

DOI: 10.1039/d4ra066618a

[rsc.li/rsc-advances](https://rsc.li/rsc-advances)

## Introduction

The design and development of anticancer drug molecules with promising efficacy and reduced toxicity remain challenging in modern scientific research. Natural products and their variants are, by and large, preferable choices owing to their fewer or no side effects with high selectivity and efficacy. In this context, curcumin, an active principle of the plant *Curcuma longa*, commonly known as turmeric, is a well-known and extensively investigated natural product. Curcumin and its variants have been established to possess a broad spectrum of biological activities, including anticancer activity.<sup>1–4</sup> Several studies have shown that CUR modulates/regulates multiple cellular and molecular targets, such as transcription factors, growth factors and their receptors, nuclear factors, and protein kinases, which may account for its broad spectrum of biological activity<sup>3,5–8</sup> and fewer or no side effects.<sup>2,9</sup> In addition, curcumin has been shown to be extremely safe even at high doses, 12 g per day, in various animal models and human studies.<sup>2,10</sup> Despite its promising therapeutic properties and safety profile, curcumin is not

approved as a therapeutic agent owing to its poor absorption, low bioavailability, rapid metabolism (*via* reduction and conjugation pathways in the liver and intestinal wall)<sup>11,12</sup> and rapid systemic clearance of what little is absorbed.<sup>5,9,12,13</sup> Curcumin's olefinic bonds, active methylene carbon, phenolic-OH and  $\beta$ -diketone have been established as primary reaction sites for its weak pharmacokinetic profile.<sup>10,12</sup> At the same time, SAR studies revealed that these functional groups are important for curcumin's therapeutic effect.<sup>5</sup> Thus, modifications altering these sites modify curcumin's pharmacokinetic profile and biological action. In earlier reports, modification of curcumin was primarily focused on aryl substitution,  $\beta$ -diketone, and active methylene carbon.<sup>5,6</sup> Studies pertaining to modification at the olefinic bond are limited and have been scarcely explored. For example, Koo *et al.* (2015) reported a set of curcumin derivatives with a methyl group introduced at olefinic bonds at the C2 and C6 positions or the C2 position only of CUR. The methyl substitution created steric hindrance and thus prevented reductive metabolism of CUR as well as contributed to the enhancement of the bioavailability of CUR. Moreover, these compounds showed enhanced antiangiogenesis and antitumor activity against glioma, U87MG, in comparison with the parent compound, CUR.<sup>14</sup>

On the other hand, combretastatin A-4 (CA-4), a *cis*-stilbenoid, isolated from the bark of the South African bush willow tree *Combretum caffrum* is a well-known microtubule depolymerizing agent.<sup>15–17</sup> Several preclinical studies have shown that CA-4 is a potent anticancer agent.<sup>16,18,19</sup> It binds to the colchicine site of tubulin and inhibits tubulin polymerization and arrests

*Dept. of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Chennai Campus, Vandalur-Kelambakkam Road, Chennai 600127, Tamil Nadu, India. E-mail: Saravanakumar.r@vit.ac.in; Fax: +91 44 3993 2555; Tel: +91 44 3993 1479*

† Electronic supplementary information (ESI) available. CCDC 2383033. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d4ra066618a>






Fig. 1 Schematic representation of novel CA-4-integrated curcumin.

the cell cycle in the metaphase and triggers apoptosis.<sup>16,20</sup> Also, it was found to be a potent vascular disrupting agent.<sup>16,18,20</sup> Structure–activity relationship (SAR) studies suggested that trimethoxy substitution on the ring A and *cis*-configuration of the olefinic bond are crucial for its bioactivity (Fig. 1).<sup>16,18–20</sup> Despite its high efficacy, CA-4 is vulnerable to undergoing transformation from the active *cis*-form to the inactive *trans* form under *in vivo* conditions.<sup>16,18,19</sup> Several variants of CA-4 have been synthesized to improve its water solubility, pharmacological properties, and stability.<sup>16,19</sup> One of the strategies that has been widely adopted is locking the *cis*-configuration of the olefinic bond into heterocyclic rings, such as imidazole, pyrazole,  $\beta$ -lactam, and triazole.<sup>16</sup> However, many of the fused cyclic ring compounds displayed inferior antiproliferative activity than the parent compound, CA-4.<sup>16,19</sup> Recently, Surendra R. Punganuru *et al.* (2016)<sup>21</sup> adopted a different strategy to suppress the *cis*–*trans* isomerization. They realized that insertion of the aryl group to the olefinic bond (C-7 position) of piperlongumine (PL) (an active principle of long pepper) would create a stabilized CA-4-like structure locked in its *cis*-form while retaining the PL configuration. The new compounds

exhibited potent antiproliferative activities against eight cancer cell lines, including the breast cancer cells MCF-7 and SKBR3. In another interesting study, a combination of curcumin (CUR) and combretastatin-A4 phosphate loaded in a nanodrug-delivery system (*i.e.* glycyrrhetic acid (GA)-modified liposomes (GA LPs)) was studied for liver-targeted co-delivery. It was found to have higher cytotoxicity than the free drug molecules.<sup>22,23</sup> The above study suggests a combination of curcumin and combretastatin-A4 works synergistically and has a better therapeutic effect. Keeping the above facts in mind, we designed and synthesized a new molecular skeleton that incorporates the structural features of both the natural products, curcumin and CA-4 (Fig. 1). Interestingly, the substitution of a phenyl group at the C2 and/or C6 positions of CUR integrated a CA-4 like structure to CUR. The new molecular skeleton now incorporated structural features of both CUR and CA-4 and has the following benefits:

(a) *Cis*-configuration of CA-4 is locked to CUR, which is crucial for its anticancer activity. This was confirmed by single-crystal XRD structural analysis.


(b) Aryl substitution creates a steric barrier around the olefinic bond against reductive metabolizing enzymes and thus retards/prevents reductive metabolism, one of the major metabolic pathways leading to the low bioavailability of CUR.

(c) Key structural features responsible for the bioactivities of both CUR and CA-4 were retained, ensuring the innate activity of both CUR and CA-4 as well as their synergistic effect, offering improved efficacy, bioavailability, stability and selectivity.

Moreover, CUR derivatives with substitution at olefinic bonds (C2, and/or C6 positions) remain underexplored molecular architectures. Thus, our research represents an exciting step forward in exploring the medicinal chemistry and synergism of both natural products, CA-4 and CUR (Fig. 1).

## Results and discussion


Our group is actively involved in the synthesis of curcumin hybrid molecules. In this context, we designed and synthesized



Scheme 1 Retrosynthesis analysis of CA-4-integrated curcumin.



Table 1 Synthesis of phenyl 2,4-diones and di-phenyl 2,4-diones




a novel molecular skeleton, combretastatin A4-integrated curcumin. Retrosynthesis analysis of the same is outlined in Scheme 1. The target molecules could be readily synthesized from diketones and benzaldehydes. The diketones in turn could be obtained from phenylacetone and ethyl acetates (Scheme 1).

### Synthesis of diketones

Claisen condensation of phenyl acetones with esters (ethyl/ethyl phenyl acetate) under basic conditions yielded  $\beta$ -diketones in

moderate yields (42–52%, Table 1). A literature-reported procedure was adopted for the synthesis of  $\beta$ -diketone.<sup>24</sup> Initially, the reaction was attempted with various bases ( $\text{NaNH}_2$ ,  $\text{KOTBu}_3$ ,  $\text{KOH}$ ,  $\text{K}_2\text{CO}_3$ , and  $\text{DBU}$ ) and solvents (THF, DMF, diethyl ether, toluene, methyl tertiary butyl ether (MTBE), and di-isopropyl ether (DIPE)). Sodamide and diethyl ether were found to be a suitable base and solvent to obtain the expected product in better yields. Phenyl 2,4-diones were prepared by reacting phenyl acetones with ethyl acetates (Table 1,  $\text{Z} = \text{H}$ ),

Table 2 Synthesis of mono-combretastatin A4-integrated curcumins




and di-phenyl 2,4-diones were prepared by reacting phenyl acetones with phenyl ethyl acetates (Table 1, Z = Ar). The synthesized diketones were characterized by  $^1\text{H}$  NMR,  $^{13}\text{C}$  NMR, and LC-MS (refer ESI $^\dagger$ ). The characterization data aligned with the structural attributes of diketones (refer to the ESI $^\dagger$ ).

The precursors, phenyl 2,4-diones and di-phenyl 2,4-diones, synthesized were then condensed with vanillin/di or trimethoxy benzaldehydes to form mono- and di-combretastatin A4-integrated curcumins (Tables 2 and 3). Accordingly, phenyl 2,4-dione/di-phenyl 2,4-dione was reacted with benzaldehyde in the presence of boron trioxide ( $\text{B}_2\text{O}_3$ ), trialkyl borate, and *n*-butylamine. A literature-reported $^{4-6}$  synthetic protocol was adopted. In all of these methods, the initial step involved the

formation of a 2,4-diketone–boron complex, which prevents Knoevenagel condensation between 2,4-diketone and benzaldehyde. A primary/secondary amine is used as a base to provide the necessary basicity for deprotonating the alkyl groups of the diketone. To eliminate the water generated during the condensation reaction, a scavenger, like alkyl borate, was used. Failure to remove the water can lead to its reaction with the diketone complex, thereby diminishing the yield of the target compounds. After completion, the reaction was acidified to break down the 2,4-diketone–boron complex and to form the expected product, mono/di-combretastatin A4-integrated curcumins in a 32–56% yield. The synthesis of mono- and di-

Table 3 Synthesis of di-combretastatin A4-integrated curcumins






Fig. 2 ChemDraw structure of compound **1da** with <sup>1</sup>H NMR peak values (in ppm) marked (refer ESI, Fig. 21†).

combretastatin A4-integrated curcumins is outlined in Tables 2 and 3.

The formation of mono- and di-combretastatin A4-integrated curcumins was confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR, FT-IR, and HR-MS. The <sup>1</sup>H and <sup>13</sup>C NMR spectral data were in accordance with the structural attributes of the mono- and di-combretastatin A4-integrated curcumins (refer to the ESI†). The structural elucidation of one of the di-combretastatin A4-integrated curcumins (**1da**) is described as a representative example (Fig. 2). NMR was recorded in DMSO-*d*<sub>6</sub> at room temperature (25 °C). The broad singlet observed at 9.56 ppm was assigned to the phenolic -OH proton. The characteristic active methylene proton appeared as a singlet at 4.97 ppm. A distinct singlet at 3.76 ppm was assigned to the methoxy (-OCH<sub>3</sub>) proton adjacent to the phenolic group. The other methoxy proton peak merged with DMSO-H<sub>2</sub>O water and appeared as a broad singlet at 3.35 ppm. A representative AB-type doublet at 6.94 and 6.86 ppm was assigned to *para*-substituted phenyl protons. A doublet of doublet at 6.71 ppm corresponded to protons *para* to a methoxy group. A doublet at 6.63 ppm was designated to protons *ortho* to a phenolic group. An entwined doublet at 6.53 ppm was assigned to protons *ortho* to a methoxy group. <sup>13</sup>C NMR showed a characteristic downfield signal for carbonyl carbon at 185.5 ppm. A distinct peak noticed at 159.2 ppm was assigned to β-olefinic carbon. Aromatic carbon signals were observed in the range of 148.8–114.0 ppm. A positive signal at 100.1 was assigned to active methylene carbon. Two peaks around 55.5 and 55.1 were designated to methoxy carbons. The FT-IR

spectrum featured characteristic -OH stretching band around 3358 cm<sup>-1</sup> and keto carbonyl (-C=O) stretching band around 1591 cm<sup>-1</sup>. The high-resolution mass spectrum showed a molecular mass corresponding to [M + H]<sup>+</sup> ion, which matched with the corresponding calculated mass. Further, the structure of one of the di-combretastatin A4-integrated curcumins (**1ca**) was unambiguously established by single-crystal X-ray diffraction analysis (Fig. 3).

### Single-crystal X-ray structure

A saturated solution of **1ca** in toluene was allowed to evaporate slowly at room temperature. Pale yellow needle-shaped crystals were formed after a week. The quality of the crystals was found to be suitable for single-crystal X-ray diffraction studies. The compound crystallized in the triclinic system with the *P* $\bar{1}$  space group (Fig. 3). From the crystal structure, it is clear that the CA-4 unit integrated into curcumin was locked in its *cis*-form, a crucial structural feature required for its biological activities. In the solid-state structure, combretastatin A4-integrated curcumin is in its enol form and the enol hydrogen is involved in intra- and intermolecular hydrogen bonding. Also, the enol oxygen is involved in aromatic C-H...O hydrogen bonds with adjacent molecules. The phenolic -OH groups are involved in hydrogen bonds with the phenolic -OH and -OCH<sub>3</sub> of adjacent molecules and contribute to the stability of the solid-state structure (Fig. 3).

### Synthesis of pyrazole derivatives of combretastatin A-4-integrated curcumin

The therapeutic potential of curcumin is mainly hampered by its poor absorption, rapid metabolism (*via* reduction and conjugation pathways at the liver and intestinal wall),<sup>11,12</sup> and rapid systemic clearance of what little is absorbed.<sup>13</sup> Thus, variants of curcumin have been synthesized to improve its pharmacokinetic profile and bioactivities. One such class of derivative that is widely known and studied is curcumin pyrazoles, which possess improved pharmacological properties and metabolic stability compared to curcumin. For example, Jeong Kwon *et al.*<sup>25</sup> showed that curcumin pyrazole could effectively inhibit the proliferation of bovine aortic endothelial cells (BAECs) at a very low concentration (IC<sub>50</sub> = 520 nM) with no cell toxicity. They also found that curcumin pyrazole could





Fig. 3 Single-crystal X-ray structure of combretastatin A4-integrated curcumin (**1ca**), (a) ORTEP diagram and (b) equivalent ChemDraw structure of **1ca**.

Table 4 Synthesis of pyrazole derivatives of combretastatin A-4-integrated curcumin



be a potent anti-angiogenic agent. Similarly, in another report, Narlawar and co-workers<sup>26</sup> found that curcumin pyrazole could inhibit the development of fibrillar A $\beta$ 42 and tau protein aggregation, with a 100-fold better activity than the parent compound, CU. Avadheshia Surolia *et al.*<sup>27</sup> unveiled that curcumin pyrazoles are seven to nine times more potent than curcumin against chloroquine-sensitive (CQ-S) and chloroquine-resistant (CQ-R) *Plasmodium falciparum*. In this context, we intended to prepare combretastatin A4-integrated curcumin pyrazole derivatives (Table 4) with the hope of improving the pharmacological properties and aqueous solubility. Accordingly, the synthesized combretastatin A4-integrated curcumins (**1db** and **1dc**) were reacted with hydrazine hydrate in acetic acid at  $60^\circ\text{C}$  (oil bath) for 12 h to form their pyrazole derivatives (Table 4). A literature-reported procedure was adopted for the synthesis of pyrazole derivatives of curcumin. In principle, this simple modification should alter the compound's properties, including its pharmacological profile, solubility, and pharmacokinetic profile.

## Conclusion

A logical design and synthesis of novel target compounds, combretastatin A4-integrated curcumins, was demonstrated. Coupling a phenyl group at the C2 and/or C6 position of curcumin integrated a combretastatin A4-like structure to curcumin to form the target compounds. A simple condensation of benzaldehyde with phenyl 2,4-dione/di-phenyl 2,4-dione *via* a modified Pabon procedure led to combretastatin A4-integrated curcumins in moderated yields. The target compounds were characterized by  $^1\text{H}$ ,  $^{13}\text{C}$  NMR, and HR-MS. Further, the structure of one of the target compounds (**1ca**) was unambiguously established by single-crystal X-ray diffraction. The single-crystal X-ray diffraction study revealed that combretastatin A4 was locked in its *cis*-configuration, a crucial structural feature responsible for its pharmacological activity. To widen the scope, pyrazole derivatives of two of the

combretastatin A4-integrated curcumins were synthesized and characterized. Thus, our findings unveiled a new molecular skeleton to be investigated with positive hopes for a better pharmacokinetic profile, and biological activity, with less or no side effects.

## Data availability

The full experimental data related to this article are given in the ESI,<sup>†</sup> including the synthetic procedure, FT-IR spectra of combretastatin A4-integrated curcumins,  $^1\text{H}$  NMR, and  $^{13}\text{C}$  NMR spectra of the combretastatin A4-integrated curcumins and their precursors. CIF data of combretastatin A4-integrated curcumin (**1ca**) are deposited in the Cambridge Crystallographic Data Centre (CCDC) and its CCDC number is 2383033.

## Conflicts of interest

Authors have no conflict of interest to declare.

## Acknowledgements

P. P. and R. S. K. thanks, Dept. of Chemistry and VIT Chennai, for providing infrastructure and instrumentation facilities (GC-MS FT-IR). SAIF, VIT Vellore is gratefully acknowledged for recording  $^1\text{H}$  and  $^{13}\text{C}$  NMR, single-crystal XRD and HR-MS.

## References

- 1 G. Sa, T. Das, S. Banerjee and J. Chakraborty, *Al Ameen J. Med. Sci.*, 2010, **3**, 21–37.
- 2 V. Soleimani, A. Sahebkar and H. Hosseinzadeh, *Phytother. Res.*, 2018, **32**, 985–995.
- 3 A. B. Kunnumakkara, D. Bordoloi, G. Padmavathi, J. Monisha, N. K. Roy, S. Prasad and B. B. Aggarwal, *Br. J. Pharmacol.*, 2017, **174**, 1325–1348.



- 4 F. Alibeiki, N. Jafari, M. Karimi and H. P. Dogaheh, *Sci. Rep.*, 2017, **7**, 2559.
- 5 P. Anand, S. G. Thomas, A. B. Kunnumakkara, C. Sundaram, K. B. Harikumar, B. Sung, S. T. Tharakan, K. Misra, I. K. Priyadarsini, K. N. Rajasekharan and B. B. Aggarwal, *Biochem. Pharmacol.*, 2008, **76**, 1590–1611.
- 6 B. Aggarwal, L. Deb and S. Prasad, *Molecules*, 2014, **20**, 185–205.
- 7 P. Anand, C. Sundaram, S. Jhurani, A. B. Kunnumakkara and B. B. Aggarwal, *Cancer Lett.*, 2008, **267**, 133–164.
- 8 B. Kocaadam and N. Şanlıer, *Crit. Rev. Food Sci. Nutr.*, 2017, **57**, 2889–2895.
- 9 P. Anand, A. B. Kunnumakkara, R. A. Newman and B. B. Aggarwal, *Mol. Pharm.*, 2007, **4**, 807–818.
- 10 G. Liang, L. Shao, Y. Wang, C. Zhao, Y. Chu, J. Xiao, Y. Zhao, X. Li and S. Yang, *Bioorg. Med. Chem.*, 2009, **17**, 2623–2631.
- 11 M. J. Yoon, Y. J. Kang, J. A. Lee, I. Y. Kim, M. A. Kim, Y. S. Lee, J. H. Park, B. Y. Lee, I. A. Kim, H. S. Kim, S.-A. Kim, A.-R. Yoon, C.-O. Yun, E.-Y. Kim, K. Lee and K. S. Choi, *Cell Death Dis.*, 2014, **5**, e1112.
- 12 M. H. Pan, T. M. Huang and J. K. Lin, *Drug Metab. Dispos.*, 1999, **27**, 486–494.
- 13 C. Tamvakopoulos, K. Dimas, Z. D. Sofianos, S. Hatziantoniou, Z. Han, Z.-L. Liu, J. H. Wyche and P. Pantazis, *Clin. Cancer Res.*, 2007, **13**, 1269–1277.
- 14 H.-J. Koo, S. Shin, J. Y. Choi, K.-H. Lee, B.-T. Kim and Y. S. Choe, *Sci. Rep.*, 2015, **5**, 14205.
- 15 S. Aprile, E. Del Grosso, G. C. Tron and G. Grosa, *Drug Metab. Dispos.*, 2007, **35**, 2252–2261.
- 16 Z. S. Seddigi, M. S. Malik, A. P. Saraswati, S. A. Ahmed, A. O. Babalghith, H. A. Lamfon and A. Kamal, *Med. Chem. Commun.*, 2017, **8**, 1592–1603.
- 17 K. G. Pinney, C. Jelinek, K. Edvardsen, D. J. Chaplin and G. Pettit, The discovery and development of the combretastatins, in *Anticancer Agents from Natural Products*, CRC Press, 2005.
- 18 G. C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Busacca and A. A. Genazzani, *J. Med. Chem.*, 2006, **49**, 3033–3044.
- 19 Q. Li and H. L. Sham, *Expert Opin. Ther. Pat.*, 2002, **12**, 1663–1702.
- 20 L. Li, S. Jiang, X. Li, Y. Liu, J. Su and J. Chen, *Eur. J. Med. Chem.*, 2018, **151**, 482–494.
- 21 S. R. Punganuru, H. R. Madala, S. N. Venugopal, R. Samala, C. Mikelis and K. S. Srivenugopal, *Eur. J. Med. Chem.*, 2016, **107**, 233–244.
- 22 H. Jiang, Z.-P. Li, G.-X. Tian, R.-Y. Pan, C.-M. Xu, B. Zhang and J. Wu, *Int. J. Nanomed.*, 2019, **14**, 1789–1804.
- 23 A. Reeves, E. Wickstrom and S. Vinogradov, *Curcumin-Combretastatin Nanocells as Breast Cancer Cytotoxic and Antiangiogenic Agent*, 2008, <https://apps.dtic.mil/sti/tr/pdf/ADA494015.pdf>.
- 24 E. C. Y. Woon, P. T. Sunderland, H. A. Paine, M. D. Lloyd, A. S. Thompson and M. D. Threadgill, *Bioorg. Med. Chem.*, 2013, **21**, 5218–5227.
- 25 J. S. Shim, D. H. Kim, H. J. Jung, J. H. Kim, D. Lim, S.-K. Lee, K.-W. Kim, J. W. Ahn, J.-S. Yoo, J.-R. Rho, J. Shin and H. J. Kwon, *Bioorg. Med. Chem.*, 2002, **10**, 2987–2992.
- 26 R. Narlawar, M. Pickhardt, S. Leuchtenberger, K. Baumann, S. Krause, T. Dyrks, S. Weggen, E. Mandelkow and B. Schmidt, *ChemMedChem*, 2008, **3**, 165–172.
- 27 S. Mishra, K. Karmodiya, N. Surolia and A. Surolia, *Bioorg. Med. Chem.*, 2008, **16**, 2894–2902.

